Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...

The FDA's approval of Biogen's Aduhelm for Alzheimer's disease has emboldened Eli Lilly to move forward plans to file its own candidate donanemab later this year, although it acknowledges it will ...

The Mini-Mental State Examination (MMSE) continues to be the most widely used screening instrument for Alzheimer's disease (AD). However, the test has been criticized along several lines ...

A new medication called donanemab appears to slow memory loss, giving patients the gift of more time. UW Medicine's Memory & Brain Wellness Center at Harborview Medical Center recently started ...

Alzheimer’s disease, a relentless condition that steals memory and independence, now has a powerful new opponent: donanemab (brand name Kisluna). This newly approved intravenous (IV) infusion ...